Clinical Trial

A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough - China Extension

Name: A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough - China Extension — clinical trial record (NCT07650084)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: CALM-2

Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of BLU-5937 in participants with Refractory Chronic Cough (RCC).

Trial Details

NCT Number	NCT07650084
Lead Sponsor	GlaxoSmithKline
Conditions	Refractory Chronic Cough
Enrollment	75 participants
Start Date	2025-11-21
Primary Completion	2027-08-27 (estimated)
Study Completion	2028-06-02 (estimated)
Updated on ClinicalTrials.gov	2026-06-16